Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Regeneron

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga · Nov 26, 2024

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga · Nov 25, 2024

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is expected to report its fiscal third-quarter earnings this month, and analysts project a single-digit profit plunge.

Barchart · Oct 17, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Barchart · Sep 4, 2024

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Barchart · Aug 28, 2024

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

Barchart · Jul 18, 2024

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Barchart · Jun 11, 2024

Read news from The Economist, FT, and more,
with one subscription

Regeneron To Defend Against DOJ Complaint On Drug Pricing

Regeneron faces DOJ legal challenge over drug-price manipulation allegations, vows to defend itself. Case could impact pharmaceutical industry and drug pri...

Top News · Jan 8, 2024

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com · Nov 1, 2023

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com · Oct 12, 2023

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · Sep 25, 2023

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com · Sep 19, 2023

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

StockNews.com · Sep 11, 2023

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

Tribune News Service · May 24, 2023

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard · Nov 7, 2022

What was the longest-running Covid infection and how were they cured?

A British man tested positive for Covid for more than two years and survived - but many more have Long Covid

Tribune News Service · Nov 6, 2022

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

The Denver Post · Sep 21, 2022

A Colorado teen’s long COVID isn’t just persisting — after 2 years, it’s getting worse

DENVER -- Reminders of life outside Lilly Downs’ Denver hospital room dotted the walls.

Benzinga · Aug 31, 2022

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

The Independent UK · Jul 21, 2022

How Donald Trump’s fight with Covid unfolded two years before Biden diagnosis

Low blood oxygen levels and lung issues led officials to believe Trump might have to be put on ventilator in 2020

Benzinga · Jul 1, 2022

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Benzinga · Jun 29, 2022

U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

1 2 3 4

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

353 stories

Bayer

271 stories

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.